Compare UNB & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UNB | VANI |
|---|---|---|
| Founded | 1891 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.6M | 119.0M |
| IPO Year | 1999 | 2014 |
| Metric | UNB | VANI |
|---|---|---|
| Price | $23.35 | $1.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | 2.7K | ★ 199.0K |
| Earning Date | 04-15-2026 | 05-14-2026 |
| Dividend Yield | ★ 5.76% | N/A |
| EPS Growth | ★ 25.52 | N/A |
| EPS | ★ 1.25 | N/A |
| Revenue | N/A | ★ $4,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.80 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $20.65 | $0.92 |
| 52 Week High | $26.41 | $1.92 |
| Indicator | UNB | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 41.58 | 42.25 |
| Support Level | $22.95 | $1.13 |
| Resistance Level | $24.22 | $1.25 |
| Average True Range (ATR) | 0.27 | 0.06 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 7.81 | 17.39 |
Union Bankshares Inc operates as a community bank in the financial services industry. It offers retail and commercial banking services to its customers through its branches, ATMs, telebanking, and internet banking systems. The Company has one definable business segment, Union Bank, which provides full retail, commercial, municipal banking, and wealth management and trust services throughout its 18 branch banking locations, three loan centers, and several ATMs covering northern Vermont and northern New Hampshire. In addition, it also offers fiduciary and asset management services through its Asset Management Group.
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.